NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $13.54 +0.52 (+3.99%) (As of 11/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Neumora Therapeutics Stock (NASDAQ:NMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neumora Therapeutics alerts:Sign Up Key Stats Today's Range$13.00▼$13.5850-Day Range$10.46▼$16.9652-Week Range$8.33▼$21.00Volume1.27 million shsAverage Volume1.39 million shsMarket Capitalization$2.17 billionP/E RatioN/ADividend YieldN/APrice Target$21.67Consensus RatingModerate Buy Company OverviewNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Read More… Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Neumora Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreNMRA MarketRank™: Neumora Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 572nd out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingNeumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageNeumora Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Neumora Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Neumora Therapeutics are expected to decrease in the coming year, from ($1.48) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neumora Therapeutics is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neumora Therapeutics is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neumora Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.41% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 6.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.41% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 6.92%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.02 News SentimentNeumora Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Neumora Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,390,513.00 in company stock.Percentage Held by Insiders26.40% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neumora Therapeutics' insider trading history. Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRA Stock News HeadlinesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Director Matthew K. Fust Sells 14,049 SharesOctober 19, 2024 | insidertrades.comInsider Selling: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Sells 5,563 Shares of StockOctober 12, 2024 | insidertrades.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 10, 2024 | Colonial Metals (Ad)JP Morgan Downgrades Neumora Therapeutics (NMRA)November 6, 2024 | msn.comCautious Hold on Neumora Therapeutics Amid Uncertainty in KOASTAL-1 Trial OutcomesNovember 6, 2024 | markets.businessinsider.comNeumora Therapeutics to Participate in Upcoming Conferences in NovemberNovember 6, 2024 | globenewswire.comContrasting Neumora Therapeutics (NMRA) & Its RivalsNovember 2, 2024 | americanbankingnews.comStifel Nicolaus Remains a Buy on Neumora Therapeutics, Inc. (NMRA)October 12, 2024 | markets.businessinsider.comSee More Headlines NMRA Stock Analysis - Frequently Asked Questions How have NMRA shares performed this year? Neumora Therapeutics' stock was trading at $17.05 at the start of the year. Since then, NMRA stock has decreased by 20.6% and is now trading at $13.54. View the best growth stocks for 2024 here. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its earnings results on Tuesday, August, 6th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37). When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share. Who are Neumora Therapeutics' major shareholders? Top institutional shareholders of Neumora Therapeutics include Auour Investments LLC (0.16%), LMR Partners LLP, Handelsbanken Fonder AB (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Kristina Burow, Robert A Lenz and Joshua Pinto. View institutional ownership trends. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neumora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP). Company Calendar Last Earnings8/06/2024Today11/10/2024Next Earnings (Confirmed)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NMRA CUSIPN/A CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees108Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$30.00 Low Stock Price Target$13.00 Potential Upside/Downside+60.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.35% Return on Assets-57.85% Debt Debt-to-Equity RatioN/A Current Ratio17.23 Quick Ratio17.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book4.41Miscellaneous Outstanding Shares160,030,000Free Float117,781,000Market Cap$2.17 billion OptionableOptionable Beta3.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:NMRA) was last updated on 11/10/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredI Got FiredStarting off with a few hundred bucks, it wasn't long before I started generating $1,000 a day. Then $10,00...Opportunistic Trader | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.